Use of intra-aortic balloon pump

Series
Cardiovascular
Status
Published
Date
Number of report
076

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for the use of intra-aortic balloon pump (IABP) in cardiogenic shock in Europe.

The following scenarios will be considered:

  • Use of IABP for treatment of cardiogenic shock in unstable angina or acute myocardial infarction;
  • Use of IABP in high-risk PCI for unstable angina or acute myocardial infarction.

The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of intra-aortic balloon pump (myocardial infarction and unstable angina, complicated by cardiogenic shock) include:

  • Abiomed (iPulse)
  • Insightra Medical (ULTRA 7FR)
  • Getinge (Cardiosave, CS)
  • Senko Medical (Corart)
  • Teleflex (AutoCAT2, AC3 Optimus)
  • Tokai Medical Products (7Fr-TAU)
  • Zeon Medical (Xemex)

Table of content is not available at the moment. Report is still ongoing.

13

Oct 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2021. In total, 58 recommendations for registration, modification of registration conditions, and removal of devices from the List of reimbursable products and services (LPPR) were published. Opinions concern cardiovascular, orthopedic, peripheral vascular, and other groups of devices, as well as medical aids.

Read more

08

Oct 2021

In September 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis, transapical transcatheter mitral valve-in-ring (TMVIR) after failed annuloplasty for mitral valve repair, and lateral elbow resurfacing for arthritis), and two new Medtech Innovation Briefings (Carnation Ambulatory Monitor, OrganOx metra for liver transplant). Also, one clinical guideline was updated.

Read more

23

Sep 2021

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 14763 of August 25, 2021, Tuscany Regional Healthcare has published assessments of thirteen medical devices of various therapeutic areas, including devices belonging to the obstetrics and gynecology field, as well as gastroenterology, urology, cardiovascular, endoscopy, spine, peripheral vascular, and other fields of care.

Read more

17

Sep 2021

In mid-August 2021, the Finnish Coordinating Center for Health Technology Assessment announced the release of the four accomplished rapid hospital assessments (HTA) performed by the Helsinki University Hospital. The accomplished rapid HTAs concern the cardiovascular, peripheral vascular, and endoscopy technology groups.

Read more

13

Aug 2021

In July 2021, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid hemorrhage) and four new Medtech Innovation Briefings (HealthVCF for detecting vertebral compression fractures on CT scans, trublood-prostate for triaging and diagnosing people with prostate cancer symptoms, AI technologies for detecting diabetic retinopathy, and Acumen IQ sensor for predicting hypotension risk).

Read more
(we accept only company emails)